Beacon Therapeutics reported that its X-linked retinitis pigmentosa gene therapy laruparetigene zovaparvovec (laru-zova) met the FDA-endorsed primary endpoint in a pivotal Phase II/III trial. The company cited improvements on low-luminance visual acuity (LLVA), with responder proportions in treated cohorts described against an untreated control group. The results move the program closer to potential approval discussions, with Beacon positioning the readout as a first-to-meet major goal in a rare eye disease category where some large-drug approaches have historically struggled. For investors, the milestone revives attention on commercial feasibility for gene therapies, particularly those targeting vision outcomes measurable on standardized ophthalmic scales. Following the pivotal win, the company’s next regulatory and labeling steps will determine how quickly the treatment can reach patients and whether follow-up data reinforce durability beyond the 12-month analysis window.